Skip to main content

Table 4 Standardized incidence ratios (SIRs) for cancer classified according to the GLOBOCAN categories

From: Characterization and risk estimate of cancer in patients with primary Sjögren syndrome

Cancer categories

Total (n = 1239)a

Women (n = 1145)

Men (n = 94)

Obs‡

Exp

SIR

LCI

UCI

Obs

Exp

SIR

LCI

UCI

Obs

Exp

SIR

LCI

UCI

All cancers†

121

63.77

1.9

1.59

2.27

105

56.77

1.85

1.53

2.24

16

7

2.29

1.4

3.73

Solid cancers§

60

53.1

1.13

0.88

1.46

55

47.42

1.16

0.89

1.51

5

5.68

0.88

0.37

2.12

 Thyroid

4

0.79

5.05

1.89

13.45

4

0.77

5.17

1.94

13.79

0

0.02

0

–

–

 Lip, oral cavity

4

0.99

4.05

1.52

10.8

4

0.83

4.81

1.81

12.83

0

0.16

0

–

–

 Stomach

5

2.24

2.23

0.93

5.36

5

1.98

2.53

1.05

6.07

0

0.26

0

–

–

 Kidney

3

1.67

1.8

0.58

5.57

2

1.44

1.39

0.35

5.55

1

0.23

4.39

0.62

31.14

 Brain, nervous system

2

1.17

1.72

0.43

6.86

2

1.07

1.87

0.47

7.48

0

0.1

0

–

–

 Gallbladder

1

0.77

1.3

0.18

9.2

1

0.72

1.39

0.2

9.83

0

0.05

0

–

–

 Lung

6

4.66

1.29

0.58

2.87

4

3.43

1.17

0.44

3.11

2

1.23

1.63

0.41

6.5

 Prostate

2

1.66

1.2

0.3

4.81

     

2

1.66

1.2

0.3

4.81

 Melanoma of skin

2

1.73

1.16

0.29

4.62

2

1.63

1.23

0.31

4.92

0

0.1

0

–

–

 Bladder

2

2.1

0.95

0.24

3.8

2

1.48

1.35

0.34

5.42

0

0.63

0

–

–

 Colorectal

9

10.08

0.89

0.46

1.72

9

9.02

1

0.52

1.92

0

1.06

0

–

–

 Breast

14

15.68

0.89

0.53

1.51

14

15.68

0.89

0.53

1.51

     

 Pancreas

2

2.29

0.87

0.22

3.5

2

2.1

0.95

0.24

3.8

0

0.18

0

–

–

 Cervix uteri

1

1.39

0.72

0.1

5.1

1

1.39

0.72

0.1

5.1

     

 Corpus uteri

2

3.72

0.54

0.13

2.15

2

3.72

0.54

0.13

2.15

     

 Ovary

1

2.16

0.46

0.07

3.28

1

2.16

0.46

0.07

3.28

     

Hematologicalb

50

4.54

11.02

8.35

14.54

42

4.14

10.14

7.49

13.72

8

0.39

20.34

10.17

40.67

 Leukemia

3

1.49

2.02

0.65

6.26

2

1.34

1.49

0.37

5.95

1

0.14

7.02

0.99

49.8

 MM/ID and lymphoma

47

3.05

15.41

11.58

20.51

40

2.80

14.29

10.48

19.48

7

0.25

27.91

13.31

58.54

  Hodgkin lymphoma

4

0.21

19.41

7.29

51.72

3

0.19

15.87

5.12

49.21

1

0.02

58.64

8.26

416.27

  MM/ID

31

0.86

36.17

25.44

51.43

28

0.79

35.59

24.58

51.55

3

0.07

42.58

13.73

132.03

  Non-Hodgkin lymphoma

12

1.99

6.04

3.43

10.64

9

1.82

4.94

2.57

9.49

3

0.16

18.37

5.93

56.96

  1. Obs observed, Exp expected, SIR standardized incidence ratios, LCL lower confidence limit, UCL upper confidence limit, MM/ID myeloma multiple and malignant immunoproliferative diseases
  2. aExcluding patients diagnosed with cancer before fulfillment of primary SjS criteria (n = 55) and patients with an age at SjS diagnosis <15 years (n = 6) (the age category “0–14” was excluded when SIR were computed). From 6 patients with an age at SjS diagnosis <15 years, one was diagnosed with cancer
  3. bExcluding 7 patients with hematological neoplasia not included in the GLOBOCAN categories (1 refractory cytopenia with multilineage dysplasia, 1 refractory anemia with unilineage dysplasia, 1 refractory anemia with excess blasts, 1 myelodisplastic syndrome unclassifiable, 1 mastocytosis, 1 essential thrombocythemia, and 1 angioimmunoblastic T-cell lymphoma) (see Additional file 1: Table S5) and 4 patients who developed first a solid cancer and subsequently a hematological cancer
  4. †Excluding patients with non-melanoma skin cancer (n = 4, not included in the GLOBOCAN classification) and a non-classifiable skin cancer (n = 1, uncertain whether was a melanoma or non-melanoma cancer)
  5. §Excluding 4 patients with neoplasia not included in the GLOBOCAN categories (2 endocrine, 2 ocular)
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us